Overview

Allogeneic Amniotic Mesenchymal Stem Cell Therapy for Lupus Nephritis

Status:
Completed
Trial end date:
2019-01-01
Target enrollment:
Participant gender:
Summary
This study would further evaluate the safety and efficacy of human amniotic mesenchymal stem cell (hA-MSC) for the treatment of lupus nephritis (LN).
Phase:
Phase 1
Details
Lead Sponsor:
Yan'an Affiliated Hospital of Kunming Medical University
Collaborator:
The First People's Hospital of Yunnan